Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT03205358 | Mar → Aug 2015 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT02199691 | Jul 2014 → Oct 2015 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 2 | NCT01732627 | Nov 2012 → Jan 2013 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 37 trials · 4 met primary | ||||||
| Phase 3 | NCT04936685 | Aug 2022 → Mar 2023 overdue | meningococcal infection | Sanofi Pasteur, a Sanofi Company | Active not recruiting | Met primary |
| Phase 3 | NCT03869866 | Apr 2019 → Mar 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03691610 | Oct 2018 → Oct 2023 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT03077438 | Feb → Oct 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT03205371 | Nov 2016 → Jul 2018 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT02842866 | Jul 2016 → Feb 2017 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT02752906 | Apr → Dec 2016 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-04-24 | Sanofi | Regulatory FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination sanofi.com ↗
The U.S. Food and Drug Administration (FDA) has approved a Biologics License Application for MenQuadfi TM Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-04-24 | Sanofi | FDA approves MenQuadfiTM, the latest innovation in meningococcal (MenACWY) vaccination sanofi.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACYW-TT | “MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for the prevention of invasive meningococcal disease (IMD) caused by serogroups A, C, W,...” PMID 32233961 ↗ Apr 20209“We evaluated the immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) booster in children primed with the same meningococcal...” PMID 40169489 ↗ Apr 2025 “Infants were randomized 1:1 to receive MenACYW-TT (Group 1) or another quadrivalent conjugate vaccine, MenACWY-CRM (Group 2) at ages 6-7 and 12-13 months, co-administered with...” PMID 41792337 ↗ Mar 2026 “An investigational meningococcal (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine (MenACYW-TT) could offer protection against invasive meningococcal disease in this...” PMID 32852352 ↗ Oct 2020 “Sanofi Pasteur's investigational quadrivalent (serogroups A, C, Y, and W) meningococcal tetanus-toxoid conjugate vaccine, MenACYW-TT, as a single dose” PMID 32233959 ↗ Apr 2020 “meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT), a tetanus toxoid conjugated vaccine against meningococcal serogroups A, C, W and Y” PMID 33814028 ↗ Apr 2021 “The quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) was assessed as a booster in this Phase III trial (NCT02752906).” PMID 32209015 ↗ Mar 2020 “MenACYW-TT, a quadrivalent meningococcal tetanus toxoid-conjugate vaccine, is indicated worldwide in individuals ≥ 56 years of age” PMID 41604139 ↗ Jan 2026 “MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for use in individuals ≥6 weeks of age.” PMID 32209248 ↗ Mar 2020 “MenACYW-TT was well-tolerated and immunogenic in ≥56-year-olds” PMID 32387012 ↗ May 2020 |
| Known as | MenACYW conjugate vaccine MenQuadfi | “MenACYW conjugate vaccine MenQuadfi®” NCT04936685 ↗ |
| Modality | Vaccine | “MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for the prevention of invasive meningococcal disease (IMD) caused by serogroups A, C, W,...” PMID 32233961 ↗ Apr 2020 |
| Route | Intramuscular | “0.5 milliliter (mL), Intramuscular (IM)” NCT02199691 ↗ |